Literature DB >> 22758630

Omics approaches in cystic fibrosis research: a focus on oxylipin profiling in airway secretions.

Jason P Eiserich1, Jun Yang, Brian M Morrissey, Bruce D Hammock, Carroll E Cross.   

Abstract

Cystic fibrosis (CF) is associated with abnormal lipid metabolism, intense respiratory tract (RT) infection, and inflammation, eventually resulting in lung tissue destruction and respiratory failure. The CF RT inflammatory milieu, as reflected by airway secretions, includes a complex array of inflammatory mediators, bacterial products, and host secretions. It is dominated by neutrophils and their proteolytic and oxidative products and includes a wide spectrum of bioactive lipids produced by both host and presumably microbial metabolic pathways. The fairly recent advent of "omics" technologies has greatly increased capabilities of further interrogating this easily obtainable RT compartment that represents the apical culture media of the underlying RT epithelial cells. This paper discusses issues related to the study of CF omics with a focus on the profiling of CF RT oxylipins. Challenges in their identification/quantitation in RT fluids, their pathways of origin, and their potential utility for understanding CF RT inflammatory and oxidative processes are highlighted. Finally, the utility of oxylipin metabolic profiling in directing optimal therapeutic approaches and determining the efficacy of various interventions is discussed.
© 2012 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22758630      PMCID: PMC3403728          DOI: 10.1111/j.1749-6632.2012.06580.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  94 in total

1.  Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint.

Authors:  M W Konstan; J S Wagener; A Yegin; S J Millar; D J Pasta; D R VanDevanter
Journal:  J Cyst Fibros       Date:  2010-06-19       Impact factor: 5.482

Review 2.  n-3 PUFAs in cancer, surgery, and critical care: a systematic review on clinical effects, incorporation, and washout of oral or enteral compared with parenteral supplementation.

Authors:  Barbara S van der Meij; Marian A E van Bokhorst-de van der Schueren; Jacqueline A E Langius; Ingeborg A Brouwer; Paul A M van Leeuwen
Journal:  Am J Clin Nutr       Date:  2011-09-21       Impact factor: 7.045

3.  Systematic review of N-acetylcysteine in cystic fibrosis.

Authors:  Y C Duijvestijn; P L Brand
Journal:  Acta Paediatr       Date:  1999-01       Impact factor: 2.299

4.  Epoxyeicosatrienoates are the dominant eicosanoids in human lungs upon microbial challenge.

Authors:  L Kiss; H Schütte; W Padberg; N Weissmann; K Mayer; T Gessler; R Voswinckel; W Seeger; F Grimminger
Journal:  Eur Respir J       Date:  2010-04-08       Impact factor: 16.671

5.  Crystal structure of the cystic fibrosis transmembrane conductance regulator inhibitory factor Cif reveals novel active-site features of an epoxide hydrolase virulence factor.

Authors:  Christopher D Bahl; Christophe Morisseau; Jennifer M Bomberger; Bruce A Stanton; Bruce D Hammock; George A O'Toole; Dean R Madden
Journal:  J Bacteriol       Date:  2010-01-29       Impact factor: 3.490

6.  Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury.

Authors:  Todd W Rice; Arthur P Wheeler; B Taylor Thompson; Bennett P deBoisblanc; Jay Steingrub; Peter Rock
Journal:  JAMA       Date:  2011-10-05       Impact factor: 56.272

7.  Antioxidants in cystic fibrosis. Conclusions from the CF antioxidant workshop, Bethesda, Maryland, November 11-12, 2003.

Authors:  André M Cantin; Terry B White; Carroll E Cross; Henry Jay Forman; Ronald J Sokol; Drucy Borowitz
Journal:  Free Radic Biol Med       Date:  2006-09-29       Impact factor: 7.376

8.  Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide.

Authors:  Claudine Guilbault; Gabriella Wojewodka; Zienab Saeed; Marian Hajduch; Elias Matouk; Juan B De Sanctis; Danuta Radzioch
Journal:  Am J Respir Cell Mol Biol       Date:  2008-12-04       Impact factor: 6.914

9.  Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients.

Authors:  Michael J Cox; Martin Allgaier; Byron Taylor; Marshall S Baek; Yvonne J Huang; Rebecca A Daly; Ulas Karaoz; Gary L Andersen; Ronald Brown; Kei E Fujimura; Brian Wu; Diem Tran; Jonathan Koff; Mary Ellen Kleinhenz; Dennis Nielson; Eoin L Brodie; Susan V Lynch
Journal:  PLoS One       Date:  2010-06-23       Impact factor: 3.240

10.  Genes that determine immunology and inflammation modify the basic defect of impaired ion conductance in cystic fibrosis epithelia.

Authors:  Frauke Stanke; Tim Becker; Vinod Kumar; Silke Hedtfeld; Christian Becker; Harry Cuppens; Stephanie Tamm; Jennifer Yarden; Ulrike Laabs; Benny Siebert; Luis Fernandez; Milan Macek; Dragica Radojkovic; Manfred Ballmann; Joachim Greipel; Jean-Jacques Cassiman; Thomas F Wienker; Burkhard Tümmler
Journal:  J Med Genet       Date:  2010-09-12       Impact factor: 6.318

View more
  9 in total

1.  Impact of storage conditions on metabolite profiles of sputum samples from persons with cystic fibrosis.

Authors:  Jiangchao Zhao; Charles R Evans; Lisa A Carmody; John J LiPuma
Journal:  J Cyst Fibros       Date:  2015-02-26       Impact factor: 5.482

Review 2.  Redox balance in cystic fibrosis.

Authors:  Assem G Ziady; Jason Hansen
Journal:  Int J Biochem Cell Biol       Date:  2014-03-20       Impact factor: 5.085

3.  Metabolomics analysis identifies novel plasma biomarkers of cystic fibrosis pulmonary exacerbation.

Authors:  Theresa A Laguna; Cavan S Reilly; Cynthia B Williams; Cole Welchlin; Chris H Wendt
Journal:  Pediatr Pulmonol       Date:  2015-06-26

4.  The Postprandial Effects of a Moderately High-Fat Meal on Lipid Profiles and Vascular Inflammation in Alzheimer's Disease Patients: A Pilot Study.

Authors:  Robin Altman; Alison H Keenan; John W Newman; John C Rutledge
Journal:  J Gen Pract (Los Angel)       Date:  2014

5.  Microbial, host and xenobiotic diversity in the cystic fibrosis sputum metabolome.

Authors:  Robert A Quinn; Vanessa V Phelan; Katrine L Whiteson; Neha Garg; Barbara A Bailey; Yan Wei Lim; Douglas J Conrad; Pieter C Dorrestein; Forest L Rohwer
Journal:  ISME J       Date:  2015-12-01       Impact factor: 10.302

6.  Neonatal Cord Blood Oxylipins and Exposure to Particulate Matter in the Early-Life Environment: An ENVIRONAGE Birth Cohort Study.

Authors:  Dries S Martens; Sandra Gouveia; Narjes Madhloum; Bram G Janssen; Michelle Plusquin; Charlotte Vanpoucke; Wouter Lefebvre; Bertil Forsberg; Malin Nording; Tim S Nawrot
Journal:  Environ Health Perspect       Date:  2016-11-04       Impact factor: 9.031

7.  High-Resolution Longitudinal Dynamics of the Cystic Fibrosis Sputum Microbiome and Metabolome through Antibiotic Therapy.

Authors:  Ruma Raghuvanshi; Karla Vasco; Yoshiki Vázquez-Baeza; Lingjing Jiang; James T Morton; Danxun Li; Antonio Gonzalez; Lindsay DeRight Goldasich; Gregory Humphrey; Gail Ackermann; Austin D Swafford; Douglas Conrad; Rob Knight; Pieter C Dorrestein; Robert A Quinn
Journal:  mSystems       Date:  2020-06-23       Impact factor: 6.496

8.  Oxylipin profile in saliva from patients with cystic fibrosis reveals a balance between pro-resolving and pro-inflammatory molecules.

Authors:  Vincenzo Carnovale; Alice Castaldo; Alessandro Di Minno; Monica Gelzo; Paola Iacotucci; Anna Illiano; Gabriella Pinto; Giuseppe Castaldo; Angela Amoresano
Journal:  Sci Rep       Date:  2022-04-07       Impact factor: 4.379

Review 9.  Metaproteomics to Decipher CF Host-Microbiota Interactions: Overview, Challenges and Future Perspectives.

Authors:  Pauline Hardouin; Raphael Chiron; Hélène Marchandin; Jean Armengaud; Lucia Grenga
Journal:  Genes (Basel)       Date:  2021-06-09       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.